Te-Fu Tsai
Overview
Explore the profile of Te-Fu Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
445
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai T, Hwang T, Chen P, Chen Y, Chou K, Ho C, et al.
Int J Oncol
. 2024 Nov;
65(6).
PMID: 39513598
Bladder cancer (BC) is a common malignancy and its most prevalent type is urothelial carcinoma, which accounts for ~90% of all cases of BC. The current treatment options for BC...
2.
Hwang T, Cuiu Y, Chen Y, Chen P, Tsai T, Chou K, et al.
Int J Oncol
. 2023 Apr;
62(5).
PMID: 37083075
Bladder cancer (BC) cells exhibit a high basal level of autophagy activity, which contributes to the development of a protective mechanism for cellular survival against current treatments. Hsa‑microRNA‑34a (miR‑34a) presents...
3.
Tsai T, Chang A, Chen P, Ho C, Chen H, Chou K, et al.
J Cell Physiol
. 2022 Jul;
237(9):3587-3597.
PMID: 35903922
A high basal level of autophagic flux in bladder cancer (BC) cells prevents cell death and weakens chemotherapy efficacy. However, how autophagy influences cancer-associated immunosuppression in BC remains undetermined. In...
4.
Hwang T, Chen P, Tsai T, Lin J, Chou K, Ho C, et al.
Cell Death Dis
. 2022 May;
13(5):514.
PMID: 35641485
No abstract available.
5.
Hwang T, Chen P, Tsai T, Lin J, Chou K, Ho C, et al.
Cell Death Dis
. 2022 Apr;
13(4):390.
PMID: 35449123
Bladder cancer (BC) is the second most common urologic cancer in western countries. New strategies for managing high-grade muscle-invasive bladder cancer (MIBC) are urgently required because MIBC has a high...
6.
Chou K, Chen P, Chang A, Tsai T, Chen H, Ho C, et al.
Environ Toxicol
. 2021 Jul;
36(11):2138-2145.
PMID: 34278709
Bladder cancer (BC), one of the most common urological neoplastic disorders in men, has an extremely low survival rate because of its tendency to metastasize. The anticancer drugs chloroquine (CQ)...
7.
Chou K, Chang A, Ho C, Tsai T, Chen H, Chen P, et al.
J Cell Mol Med
. 2021 Jun;
PMID: 34142438
Bladder cancer (BC) is the second most common urological tumour in Western countries. Approximately, 80% of patients with BC will present with non-muscle invasive bladder cancer (NMIBC), whereas a quarter...
8.
Chou K, Chang A, Tsai T, Lin Y, Chen H, Ho C, et al.
Oncol Rep
. 2021 Mar;
45(3):911-920.
PMID: 33650650
Bladder cancer (BC), a common urologic cancer, is the fifth most frequently diagnosed tumor worldwide. hsa‑miR‑34a displays antitumor activity in several types of cancer. However, the functional mechanisms underlying hsa‑miR‑34a...
9.
Ho C, Chang A, Hsu C, Tsai T, Lin Y, Chou K, et al.
Environ Toxicol
. 2020 Sep;
36(2):185-193.
PMID: 32981224
Autophagy plays a dual function in cancer progression; autophagy activation can support cancer cell survival or contribute to cell death. Miconazole, a Food and Drug Administration-approved antifungal drug, has been...
10.
Tsai T, Chen P, Lin Y, Chou K, Chen H, Ho C, et al.
Drug Des Devel Ther
. 2020 Apr;
14:1209-1218.
PMID: 32273683
Purpose: Nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or NRF2, a transcription factor capable of upregulating antioxidant response element (ARE)-mediated expression and cytoprotective proteins, plays critical roles in...